By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering GSK (GSK), which belongs to the Zacks Medical - ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...